CHMPCommittee for Medicinal Products for Human Use
CHMPCultural Heritage Management Plan
CHMPCommittee on Human Medicinal Products (European Medicines Agency)
CHMPCentrale Humanitaire Médico-Pharmaceutique
CHMPCommunity Hospital of the Monterey Peninsula (Monterey, CA)
CHMPCertified Hazardous Materials Practitioner (Institute of Hazardous Materials Managers)
References in periodicals archive ?
The CHMP granted a positive opinion for two informed consent applications for the maintenance treatment of adult patients with moderate to severe chronic obstructive pulmonary disease: CHF 5993 Chiesi Farmaceutici S.
The European Commission will now consider the CHMP positive opinion, with its decision on the approval expected in April.
It has also been recalled from the market in Canada, CHMP said.
The CHMP evaluated Soliris under the European Accelerated Assessment procedure, the fastest evaluation timeframe for full approval awarded by EMEA.
The European Commission, which has the authority to approve medicines for use in the European Union, generally follows the recommendations of the CHMP and typically renders a final decision within three months of the CHMP opinion.
The CHMP intends to hold a final vote on the treatment indication at their March meeting.
European clinicians provided valuable support to the CHMP decision and are looking forward to Pharmaxis bringing this new therapeutic treatment option to their patients in the near future," Dr.
The Committee has requested additional data, which could delay the CHMP opinion until the fourth quarter, but we will be working with the CHMP in the coming weeks to further clarify their request and the impact on timing".
M2 PHARMA-January 30, 2018-Mylan and Biocon receive positive CHMP opinion for biosimilar insulin glargine
M2 EQUITYBITES-January 26, 2018-Santhera receives negative CHMP appeal opinion for Raxone authorisation
The CHMP recommended granting marketing authorisations for two cancer medicines: Zejula (niraparib), an orphan designated medicine intended for the treatment of ovarian cancer, and Tookad (padeliporfin), for the treatment of adenocarcinoma of the prostate.
The CHMP opinion recommends that JANUVIA be approved in the European Union for the treatment of type 2 diabetes.